X4 Pharmaceuticals Inc Q4 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Kluska - Cantor Fitzgerald - Analyst : Hi, everyone. Thanks for taking the questions, and kudos. I've seen your team at a lot of these medical conferences, so great work getting the community aware of what's going on there. I wanted to ask about commercialization and thoughts around CN. So the KOLs that we speak to note that even meeting some GCSF would be a huge win, but understand that in a commercial setting, patients are going to present differently, some on monotherapy mav, some on combination, and some on combinations that may be less GCSF. So to account for this, what is your expectation on what the monitoring and neutrophil measured protocols would look like in a commercial setting?

Question: Kristen Kluska - Cantor Fitzgerald - Analyst : Yes, thank you. And maybe if I could squeeze in a second one. For WHIM syndrome, you noted that, sometimes, physicians are thinking, hey, actually, maybe I do have a patient that fits the criteria for WHIM syndrome. Curious if you're seeing any trends about what specifically it is about the indication that it's kind of putting this light bulb in their head or if you've heard any specific feedback there to help with your education efforts?

Question: Kristen Kluska - Cantor Fitzgerald - Analyst : Thanks very much.

Question: Ted Tenthoff - Piper Sandler Companies - Analyst : Great. Thank you very much. Really getting excited for the launch here. I have just a couple questions. Firstly, on the FDA side, appreciating that there's not a panel, are there any final issues to resolve in terms of manufacturing visits? Have you initiated labeling discussions? When do you think that happens, all those kinds of things? And then when it comes to the actual selling effort, how many reps do you anticipate to satisfy the US and what do you think the kind of cost would be -- annual cost for that sales force? Thanks so much.

Question: Ted Tenthoff - Piper Sandler Companies - Analyst : Okay, great. Thank you. Good luck.

Question: Sean Lee - H.C. Wainwright & Co., LLC - Analyst : Hey, good morning. This is Sean on for RK. I just have a quick question in terms of the awareness campaign. So because it's such a rare disease, once it's launched, would you be doing a marketing campaign targeting patients as well just to have the outreach there, too, so that they can start reaching out for mavorixafor? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 21, 2024 / 12:30PM, XFOR.OQ - Q4 2023 X4 Pharmaceuticals Inc Earnings Call

Question: Sean Lee - H.C. Wainwright & Co., LLC - Analyst : Great. Thank you for that.

Question: Stephen Willey - Stifel Nicolaus and Company, Incorporated - Analyst : Yeah, good morning. Thanks for taking the questions. Maybe just a couple Phase 3 CN questions. So I think you are stratifying on CN subtype in the Phase 3, but I guess I'm just wondering how you expect those subtypes to be represented within the Phase 3, given patient eligibility criteria, and if you're enrolling in a way to get kind of a minimal representation of each of these, whether it's congenital, autoimmune, or idiopathic.

Question: Stephen Willey - Stifel Nicolaus and Company, Incorporated - Analyst : Okay. And then is there a lower limit of neutrophils that a patient must have to be Phase 3 eligible? And then, I guess, just given the inherent variability of neutrophil counts, how many measurements do you require during the screening process prior to randomization?

Question: Stephen Willey - Stifel Nicolaus and Company, Incorporated - Analyst : Okay, very helpful. Thanks for taking the questions.